Sharemaestro Newsreel

Innovative Eyewear (Nasdaq: LUCY) registers 6,766,673 warrant shares

Innovative Eyewear, Inc. (Nasdaq: LUCY) has registered 6,766,673 shares of common stock for resale, which are issuable upon the exercise of outstanding Series J Investor Warrants and placement agent warrants. While the company will not receive proceeds from the resale of these shares by …

AtriCure Q2 Earnings Call Highlights

AtriCure reported strong Q2 2026 results with double-digit revenue growth and a return to GAAP profitability, driven by its pain management, appendage management, and open ablation franchises. The company raised its full-year adjusted EBITDA outlook, anticipating continued growth from these key areas while acknowledging …

AtriCure Reports Q2 2026 Results: Full Earnings Call Transcript

AtriCure (NASDAQ: ATRC) announced its Q2 2026 financial results, reporting worldwide revenue of $154 million, a 13% increase, and a U.S. revenue increase of 14%, driven by strong adoption of key products across its pain management, appendage management, and open ablation franchises. The company …

AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates

AtriCure (ATRC) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

embecta's fiscal Q3 call includes an operational update and Q&A

Embecta (Nasdaq: EMBC) is scheduled to host a conference call on Friday, August 7, 2026, at 8:00 a.m. ET to discuss its fiscal third-quarter 2026 financial results. The call will also include an operational update and a Q&A session for participants. A webcast replay …

embecta to Report Fiscal Third Quarter Financial Results

Embecta Corp. (Nasdaq: EMBC) will host a conference call on Friday, August 7, 2026, at 8:00 a.m. ET to discuss its fiscal third quarter 2026 financial results and provide an operational update. The call will also include a question and answer session. Interested parties …

Resmed Inc (0KW4) Q1 2024 Earnings Report - Results, Call & Slides

Resmed Inc. (0KW4) reported its Q1 2024 earnings, beating the consensus EPS estimate by $0.02 with an actual EPS of $1.64. The company's revenue, however, slightly missed expectations at $1.10 billion, but still represented a 16.00% year-over-year growth. The report includes details on the …

Baxter International (BAX) Projected to Release Earnings on Thursday

Baxter International (BAX) is expected to announce its Q2 2026 earnings before market open on Thursday, July 30th, with analysts projecting $0.36 EPS and $2.7927 billion in revenue. The company's previous quarterly report surpassed estimates but showed a negative net margin and lower earnings …

NXGL stock holds focus as NexGel files a quarter update

NexGel, Inc. (NASDAQ: NXGL) reported Q1 2026 revenue of $1.3 million and a net loss of $2.3 million. The company ended the quarter with $5.9 million in cash, highlighting the ongoing effort to bridge the gap between commercial scale and profitability. The hydrogel business …

West Pharmaceutical Services Inc 2Q 2026: Revenue $872.3M, EPS $2.15— 10-Q Summary

West Pharmaceutical Services Inc. (WST) reported strong results for the second quarter of 2026, with revenue reaching $872.3M and diluted EPS at $2.15, driven by high demand for proprietary products. The company saw growth in HVP components and devices, including those for biologics and …

Align Technology Announces New Innovations to Advance Invisalign® Treatment Planning and Enhance Patient Engagement Through Its Integrated Align™ Digital Platform

Align Technology (NASDAQ: ALGN) has introduced new innovations to its Align™ Digital Platform, including advanced Invisalign planning tools and enhanced patient engagement features. These updates allow doctors to visualize treatment options and outcomes more clearly, with features like 3D Tissue Animation and the Invisalign® …

ATRICURE ($ATRC) Releases Q2 2026 Earnings, Stock Rises

AtriCure reports Q2 2026 revenue $153.6M, net income $9.0M and adjusted EBITDA $27.3M

AtriCure announced strong financial results for Q2 2026, with revenue reaching $153.6 million, a 12.8% increase year over year, and a net income of $9.0 million. The company also reported an adjusted EBITDA of $27.3 million and robust cash generation, along with positive full-year …

Daxor (DXR) Proxy filing Summary

This article summarizes Daxor's (DXR) proxy filing, detailing an upcoming Annual Meeting on June 23, 2026. Key agenda items include the election of six directors and the ratification of Bush & Associates, CPA as the independent auditor for 2026. The filing also outlines corporate …

Utah Medical reports Q2 sales down 14.3% to $8.53M, net income $2.69M; 1H sales down 12.3%

Utah Medical Products (UTMD) reported Q2 2026 consolidated net sales of $8.529 million, a 14.3% decrease year-over-year, with net income of $2.686 million. First-half sales also fell by 12.3% to $17.252 million. The decline is attributed to the loss of sales from two major …

How Investors Are Reacting To Teleflex (TFX) Winning Premier Deal For Vascular Access Products

Teleflex Incorporated has secured a national group purchasing agreement with Premier, Inc. for its Arrow brand vascular access portfolio, which could expand its presence in hospital systems. This deal, along with the recent BIOTRONIK Vascular Intervention acquisition, emphasizes Teleflex's focus on vascular access and …

Kaplan Fox Reminds Embecta Corp. (EMBC) Investors Seeking Recovery of the Lead Plaintiff Deadline on August 17, 2026

Kaplan Fox & Kilsheimer LLP has announced a class action lawsuit against Embecta Corp. (EMBC) following disappointing Q2 fiscal 2026 results and a significant stock price drop. Investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, are encouraged to join …

EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit

The Rosen Law Firm is reminding purchasers of Embecta Corp. common stock (NASDAQ: EMBC) between November 25, 2025, and May 4, 2026, of the August 17, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Embecta made misleading statements regarding …

Price to sales forward of Nyxoah SA – EURONEXT:NYXH

This article provides a financial data point for Nyxoah SA (EURONEXT:NYXH), specifically its forward price-to-sales ratio. It appears to be a stub or a data entry within a larger financial information platform like TradingView, with no further analytical content. The article primarily lists navigational …

ISRG vs. ABT: Which MedTech Giant Is the Smarter Investment Now?

This article compares Intuitive Surgical (ISRG) and Abbott Laboratories (ABT), two MedTech giants, to determine which is the smarter investment. While both companies have seen stock declines in 2026, they continue to perform well in their respective core businesses. The analysis suggests that ISRG, …

Enterprise value to revenue forward of Alcon AG – SIX:ALC

This page from TradingView provides financial information for Alcon AG (SIX:ALC), specifically focusing on its enterprise value to revenue forward metric. The content highlights the company's financials, offering data and metrics for investors and analysts interested in Alcon AG's performance. The page also indicates …

Reasons to Retain Align Technology Stock in Your Portfolio for Now

Align Technology (ALGN) is expected to see significant growth due to international expansion and advancements in its iTero intraoral scanning technology. Despite potential headwinds from a dull macroeconomic environment and unfavorable foreign exchange movements affecting sales, the company's geographic expansion in EMEA and APAC, …

Teleflex Inc. stock underperforms Thursday when compared to competitors

Teleflex Inc. (TFX) shares dropped by 2.70% on Thursday, closing at $131.16, in a trading session where both the S&P 500 and Dow Jones Industrial Average also experienced declines. This marks the second consecutive day of losses for the stock. Despite the broad market …

Anteris Technologies Files Appendix 3G for New Share Issue

Anteris Technologies Global Corp. has filed an Appendix 3G for the issue of 500 new unquoted common shares dated July 22, 2026. This modest share issuance expands the company's equity base and is considered routine capital management, ensuring transparency for investors and regulators. The …

BioLife Solutions to be acquired by Repligen in $1.5B cell therapy deal

BioLife Solutions, a Bothell, Wash.-based company specializing in tools for cell and gene therapy, is set to be acquired by Repligen, a life sciences corporation, for $1.5 billion. The deal involves BioLife shareholders receiving $11.25 in cash plus 0.1442 shares of Repligen stock per …

West Pharma says sterile packaging upgrades fuel demand for high-value plastics

West Pharmaceutical Services indicates that new European Union regulations regarding materials and sterile packaging are increasing the demand for high-value plastics. This surge in interest is particularly noted in the pharmaceutical packaging sector. The article highlights how these regulatory changes are influencing material choices …

ICU Medical schedules Q2 2026 earnings call for August 6

ICU Medical Inc. (NASDAQ: ICUI) has announced that its second-quarter 2026 earnings will be released on Thursday, August 6, 2026, at approximately 4:00 p.m. ET. A conference call to discuss these results will follow at 4:30 p.m. ET. Investors can access the call via …

Repligen to Expand Cell Therapy Capabilities With BioLife Buyout

Repligen Corporation announced an agreement to acquire BioLife Solutions for approximately $1.5 billion, aiming to strengthen its position in the rapidly growing cell therapy market. This acquisition is expected to complement Repligen's existing solutions, add a high-margin consumables business, and be accretive to revenue …

Press Release: Teleflex Announces Second Quarter 2026 Earnings Conference Call Information

Teleflex (NYSE: TFX) will announce its financial results for the second quarter of 2026 before the market opens on Thursday, August 1, 2026. The company will host a conference call at 8:00 a.m. ET

The Zacks Analyst Blog Highlights Qualcomm, Intuitive Surgical, Stryker, Frequency Electronics and Good Times Restaurants

This Zacks Analyst Blog highlights research reports on several key stocks, including Qualcomm Inc. (QCOM), Intuitive Surgical, Inc. (ISRG), Stryker Corp. (SYK), Frequency Electronics, Inc. (FEIM), and Good Times Restaurants Inc. (GTIM). The report provides an overview of each company's recent performance, challenges, and …

AptarGroup (ATR) Expected to Beat Earnings Estimates: Should You Buy?

Wall Street expects a year-over-year decline in earnings on higher revenues when AptarGroup (ATR) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock …

Earnings Preview: Baxter International (BAX) Q2 Earnings Expected to Decline

The market expects Baxter International (BAX) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might …

West Pharma raises profit forecast on strong demand for injectable drug components

West Pharmaceutical Services has raised its annual profit forecast, driven by robust demand for its components used in injectable drugs. The company reported strong Q2 adjusted earnings and net sales, exceeding analyst estimates. These positive results prompted West Pharma to boost its full-year 2026 …

Garrison to retire from BD at end of fiscal year

Dr. Michael “Mike” Garrison, executive vice president and president of the Medical Essentials and BioPharma Systems segments at BD (Becton, Dickinson and Company), is retiring after more than 20 years with the company, effective October 2. During his tenure, Garrison held several leadership roles …

West Pharmaceutical (WST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended June 2026, West Pharmaceutical Services (WST) reported revenue of $872.3 million, up 13.8% over the same period last year. EPS came in at $2.37, compared to $1.84 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate …

Wall Street Analysts Think Intuitive Surgical (ISRG) Is a Good Investment: Is It?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Let's …